MA52648A - Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation - Google Patents

Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Info

Publication number: MA52648A
Authority: MA; Morocco
Prior art keywords: compounds; pharmaceutical compositions; ppar agonists; use procedures; procedures
Prior art date: 2015-10-07

Application number

MA052648A

Other languages

English (en)

Inventor

Michael Downes

Ronald M Evans

Arthur Kluge

Bharat Lagu

Masanori Miura

Sunil Kumar Panigrahi

Michael Patane

Susanta Samajdar

Ramesh Senaiar

Taisuke Takahashi

Original Assignee

Mitobridge Inc

Salk Inst Biological Studies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-07

Filing date

2016-10-05

Publication date

2021-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-05 Application filed by Mitobridge Inc, Salk Inst Biological Studies filed Critical Mitobridge Inc

2021-10-13 Publication of MA52648A publication Critical patent/MA52648A/fr

Links

102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA052648A 2015-10-07 2016-10-05 Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation MA52648A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562238629P	2015-10-07	2015-10-07
US201562243263P	2015-10-19	2015-10-19
US201662352348P	2016-06-20	2016-06-20

Publications (1)

Publication Number	Publication Date
MA52648A true MA52648A (fr)	2021-10-13

Family

ID=57200096

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA052098A MA52098A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
MA052648A MA52648A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA052098A MA52098A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Country Status (26)

Country	Link
US (6)	US10399958B2 (fr)
EP (3)	EP3770146B1 (fr)
JP (2)	JP6657413B2 (fr)
KR (2)	KR102667386B1 (fr)
CN (3)	CN108349904B (fr)
AU (3)	AU2016333963C1 (fr)
BR (1)	BR112018006866B1 (fr)
CA (1)	CA3000431A1 (fr)
CO (1)	CO2018004473A2 (fr)
DK (1)	DK3359528T3 (fr)
EA (1)	EA037371B1 (fr)
ES (3)	ES2988059T3 (fr)
HU (1)	HUE058154T2 (fr)
IL (3)	IL258225B (fr)
JO (3)	JO3738B1 (fr)
MA (2)	MA52098A (fr)
MX (3)	MX392524B (fr)
MY (1)	MY203081A (fr)
PH (1)	PH12018500762A1 (fr)
PL (1)	PL3359528T3 (fr)
PT (1)	PT3359528T (fr)
SG (1)	SG10201906400SA (fr)
TW (3)	TWI730408B (fr)
UA (1)	UA122237C2 (fr)
WO (1)	WO2017062468A1 (fr)
ZA (4)	ZA201802029B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2016333963C1 (en)	2015-10-07	2021-05-27	The Salk Institute For Biological Studies	PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en)	2016-04-13	2022-06-14	Mitobridge, Inc.	PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) *	2016-10-05	2023-01-06	米托布里奇公司	Ppar激动剂化合物的结晶和盐形式
UA124019C2 (uk) *	2016-10-05	2021-07-07	Мітобрідж, Інк.	Спосіб лікування гострого пошкодження нирок
US20220331267A1 (en) *	2019-09-05	2022-10-20	Rush University Medical Center	Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en)	2019-09-26	2023-04-25	Abionyx Pharma Sa	Compounds useful for treating liver diseases
CA3212825A1 (fr) *	2021-03-08	2022-09-15	Abionyx Pharma Sa	Composes utiles pour le traitement des maladies du foie
WO2022189856A1 (fr)	2021-03-08	2022-09-15	Abionyx Pharma Sa	Composés utiles pour le traitement des maladies du foie
WO2022256540A1 (fr)	2021-06-02	2022-12-08	Astellas Pharma Inc.	Procédés d'utilisation de composés agonistes ppar et compositions pharmaceutiques associées
WO2023147309A1 (fr)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Utilisation d'agonistes ppar-delta dans le traitement d'une maladie
EP4230196A1 (fr)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Composés à utiliser dans le traitement des dystrophinopathies
WO2025207099A1 (fr)	2024-03-28	2025-10-02	Astellas Pharma Inc.	Inhibiteurs de ppar-delta pour prévenir une fibrillation auriculaire post-opératoire

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228281A (en)	1977-09-23	1980-10-14	Ciba-Geigy Corporation	Dicarboxylic acids containing triazine rings
DE4123341A1 (de)	1991-07-15	1993-01-21	Thomae Gmbh Dr K	Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en)	1995-06-09	1995-08-02	Fujisawa Pharmaceutical Co	Benzamide derivatives
CN1348442A (zh)	1999-02-26	2002-05-08	默克公司	新的磺胺化合物及其应用
GB9919413D0 (en)	1999-08-18	1999-10-20	Zeneca Ltd	Chemical compounds
PT1311488E (pt)	2000-08-17	2009-12-30	Pfizer Ltd	Imidazóis substituídos utilizados como inibidores de tafia
CA2495943C (fr)	2002-08-29	2009-07-21	Merck & Co., Inc.	Indoles a activite antidiabetique
EP1553075B1 (fr)	2002-10-03	2013-08-14	Ono Pharmaceutical Co., Ltd.	Antagonistes des recepteurs de l'acide lysophosphatidique (lpa)
WO2004060367A1 (fr)	2002-12-30	2004-07-22	Fujisawa Pharmaceutical Co., Ltd.	Derives d'imidazole et de triazole utiles en tant qu'inhibiteurs de cox-1 selectifs
KR20070087197A (ko)	2003-09-26	2007-08-27	니뽄 다바코 산교 가부시키가이샤	잔여 리포프로테인 생산 저해 방법
JP2008512364A (ja)	2004-09-06	2008-04-24	エフ．ホフマン−ラロシュアーゲー	４−アミノメチルベンズアミジン誘導体及び第ＶＩＩａ因子阻害剤としてのその使用
KR20070097574A (ko)	2005-02-15	2007-10-04	에프. 호프만-라 로슈 아게	Ｐｐａｒ 활성화제로서의 아미드 유도체
CA2621406A1 (fr) *	2005-09-07	2007-03-15	Plexxikon, Inc.	Composes actifs sur les ppar
EP1991544B1 (fr)	2006-01-30	2018-08-15	vTv Therapeutics LLC	Derives d'imidazole a substitution, compositions et procedes d'utilisation en tant qu'inhibiteurs de ptpase
CA2644369A1 (fr)	2006-03-28	2007-10-04	Novartis Ag	Amides heterocycliques destines a une utilisation en tant que produits pharmaceutiques
EP2014652B1 (fr)	2006-04-18	2014-08-06	Nippon Chemiphar Co., Ltd.	Agent d'activation du récepteur activé par les proliférateurs des peroxisomes
DE102006023336A1 (de)	2006-05-18	2007-11-22	Merck Patent Gmbh	1,5-Diphenyl-pyrazole II
CN101085772A (zh) *	2006-06-07	2007-12-12	上海艾力斯医药科技有限公司	一类具有PPARγ激动剂活性的化合物及其应用
WO2008093639A1 (fr)	2007-01-29	2008-08-07	Takeda Pharmaceutical Company Limited	Composé de pyrazole
US20100063041A1 (en)	2007-03-07	2010-03-11	Ho-Sang Moon	Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
JP2008285452A (ja)	2007-05-21	2008-11-27	Ono Pharmaceut Co Ltd	ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CA2710764A1 (fr)	2007-12-28	2009-07-09	The Salk Institute For Biological Studies	Methodes ameliorant les performances et le tonus musculaires
ES2607482T3 (es)	2012-08-28	2017-03-31	Koc Universitesi	Placa ósea
JP2016520552A (ja)	2013-04-05	2016-07-14	ソークインスティテュートフォーバイオロジカルスタディーズ	Ｐｐａｒアゴニスト
WO2015035171A1 (fr)	2013-09-09	2015-03-12	High Point Pharmaceuticals, Llc	Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie
US20170305894A1 (en)	2014-10-08	2017-10-26	Mitobridge, Inc.	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (fr)	2014-10-08	2016-04-14	Salk Institute For Biological Studies	Agonistes de ppar et leurs méthodes d'utilisation
AU2016333963C1 (en)	2015-10-07	2021-05-27	The Salk Institute For Biological Studies	PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en)	2016-04-13	2022-06-14	Mitobridge, Inc.	PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) *	2016-10-05	2023-01-06	米托布里奇公司	Ppar激动剂化合物的结晶和盐形式
UA124019C2 (uk)	2016-10-05	2021-07-07	Мітобрідж, Інк.	Спосіб лікування гострого пошкодження нирок
PT3562822T (pt) *	2016-12-30	2021-06-02	Mitobridge Inc	Inibidores de poli-adp ribose polimerase (parp)

2016
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/fr not_active Ceased
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/fr active Active
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 CA CA3000431A patent/CA3000431A1/fr active Pending
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/fr active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/fr active Active
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-09-14 JO JOJO/P/2020/0230A patent/JOP20200230B1/ar active
- 2020-09-14 JO JOJO/P/2020/0231A patent/JOP20200231B1/ar active
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT3359528T (pt)	2022-04-07
US10399958B2 (en)	2019-09-03
EP3795566A1 (fr)	2021-03-24
TWI730006B (zh)	2021-06-11
US11578052B2 (en)	2023-02-14
US20210253549A1 (en)	2021-08-19
ZA202003663B (en)	2022-08-31
IL275392A (en)	2020-07-30
JOP20200231B1 (ar)	2022-03-14
US20230373948A1 (en)	2023-11-23
MX392524B (es)	2025-03-24
ZA202003664B (en)	2022-08-31
MX2020011100A (es)	2022-05-23
CO2018004473A2 (es)	2018-09-20
ES2949852T3 (es)	2023-10-03
WO2017062468A1 (fr)	2017-04-13
TWI742479B (zh)	2021-10-11
PH12018500762A1 (en)	2018-10-29
KR20180095797A (ko)	2018-08-28
MY203081A (en)	2024-06-07
AU2019283837B2 (en)	2020-12-24
JP6657413B2 (ja)	2020-03-04
JP6866514B2 (ja)	2021-04-28
AU2016333963B2 (en)	2021-01-07
EP3359528A1 (fr)	2018-08-15
US20190084958A1 (en)	2019-03-21
EP3770146A1 (fr)	2021-01-27
TW201943705A (zh)	2019-11-16
IL275387B (en)	2021-08-31
US10906885B2 (en)	2021-02-02
CN113024467A (zh)	2021-06-25
US20200157074A1 (en)	2020-05-21
BR112018006866B1 (pt)	2023-11-21
ZA202003662B (en)	2022-08-31
TWI730408B (zh)	2021-06-11
IL275387A (en)	2020-07-30
EP3770146B1 (fr)	2024-07-24
WO2017062468A8 (fr)	2017-05-11
MX392523B (es)	2025-03-24
US20240417383A1 (en)	2024-12-19
CN108349904B (zh)	2021-08-31
DK3359528T3 (en)	2022-03-07
NZ740846A (en)	2024-12-20
EP3795566B1 (fr)	2023-04-19
CN113024467B (zh)	2024-08-06
UA122237C2 (uk)	2020-10-12
CA3000431A1 (fr)	2017-04-13
MX380281B (es)	2025-03-12
HUE058154T2 (hu)	2022-07-28
CN108349904A (zh)	2018-07-31
AU2020281069A1 (en)	2021-01-07
TW202012375A (zh)	2020-04-01
JP2018534355A (ja)	2018-11-22
MA52098A (fr)	2021-01-27
TW201722919A (zh)	2017-07-01
PL3359528T3 (pl)	2022-05-30
US10479775B1 (en)	2019-11-19
EA037371B1 (ru)	2021-03-19
ES2906379T3 (es)	2022-04-18
KR102667385B1 (ko)	2024-05-21
JP2020075939A (ja)	2020-05-21
MX2018004295A (es)	2018-08-09
JOP20200230B1 (ar)	2024-04-18
AU2019283837A1 (en)	2020-01-16
AU2016333963A1 (en)	2018-04-12
JOP20200231A1 (ar)	2022-10-30
EP3770146C0 (fr)	2024-07-24
BR112018006866A2 (pt)	2018-10-16
ZA201802029B (en)	2022-01-26
SG10201906400SA (en)	2019-08-27
US20190337920A1 (en)	2019-11-07
HK1257907A1 (zh)	2019-11-01
KR102667386B1 (ko)	2024-05-21
MX2020011099A (es)	2022-05-23
IL258225B (en)	2021-08-31
IL258225A (en)	2018-05-31
EA201890776A1 (ru)	2018-09-28
CN113004205B (zh)	2024-07-02
AU2016333963C1 (en)	2021-05-27
CN113004205A (zh)	2021-06-22
KR20210126150A (ko)	2021-10-19
EP3359528B1 (fr)	2022-01-12
AU2020281069B2 (en)	2022-10-27
IL275392B (en)	2022-05-01
JO3738B1 (ar)	2021-01-31
JOP20200230A1 (ar)	2022-10-30
ES2988059T3 (es)	2024-11-19

Publication	Publication Date	Title
MA52098A (fr)	2021-01-27	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3665156A4 (fr)	2021-04-28	Composés, compositions et procédés
EP3676297A4 (fr)	2021-04-28	Composés, compositions et procédés
EP3778607C0 (fr)	2023-08-30	Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3504213A4 (fr)	2020-01-15	Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr)	2019-11-27	Composés anti-crispr et leurs procédés d'utilisation
EP3313404A4 (fr)	2019-08-07	Compositions thérapeutiques, associations et procédés d'utilisation
EP3316894A4 (fr)	2019-06-19	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3340988A4 (fr)	2019-05-15	Composés inhibiteurs de canaux ioniques, formulations pharmaceutiques, et utilisations
EP3307762A4 (fr)	2019-02-27	Variants de cas9 rapporteurs et leurs procédés d'utilisation
ME03417B (fr)	2020-01-20	Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3450460A4 (fr)	2019-12-25	Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation
MA48942A (fr)	2020-04-08	Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3364984A4 (fr)	2019-09-25	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3845528A4 (fr)	2022-05-11	Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées
EP3334719A4 (fr)	2019-02-06	Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
MA49560A (fr)	2020-05-20	Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3380525A4 (fr)	2019-11-13	Formulations pharmaceutiques et leurs procédés d'utilisation
EP3383853A4 (fr)	2019-06-19	Dérivés d'homobispypéridinyle en tant qu'agonistes des oxystérols bêta, compositions et leur utilisation
EP3468555A4 (fr)	2020-04-01	Composés antimicrobiens et leurs procédés d'utilisation
EP3496768A4 (fr)	2020-04-15	Compositions antimicrobiennes et procédés d'utilisation associés.
MA46543A (fr)	2019-08-21	Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
MA42527A (fr)	2021-04-07	Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
EP3349755A4 (fr)	2019-04-24	Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP3350196A4 (fr)	2019-04-03	Composés carborane et leurs procédés d'utilisation